-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Spyre Therapeutics, Raises Price Target to $115

Benzinga·08/05/2026 15:05:56
Listen to the news
Wells Fargo analyst Yanan Zhu maintains Spyre Therapeutics (NASDAQ:SYRE) with a Overweight and raises the price target from $90 to $115.